Corporate Information, English, IR, News, Other Corporate Information

Board member purchases shares in Acarix

12 Sep

Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Dr. Tony Daz, Board member of Acarix, purchased 2,000,600 shares in the company between September 9 and September 11 at an average price of USD 0.031 per share. His total ownership amounts to 2,000,600 shares.

“I have great faith in the company and its product. The Acarix system is a disruptive technology to rapidly rule out CAD in a cost-effective way and I believe it will change the way we approach initial patient evaluation for chest pain.” comments Dr. Tony Das.

For more information contact:
Jennifer Monies, phone +1 (405) 550-8144, jmonies@saxum.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Board member purchases shares in Acarix

Board member purchases shares in Acarix
Newer Acarix announces outcome of warrant exercise of series 3
Back to list
Older Acarix informs of exercise price for the warrants of series TO 3